Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Army
Daiichi Sankyo
Argus Health
Boehringer Ingelheim
Queensland Health

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,958,335

« Back to Dashboard

Which drugs does patent 6,958,335 protect, and when does it expire?

Patent 6,958,335 protects GLEEVEC and is included in two NDAs. There have been two Paragraph IV challenges on Gleevec.

Protection for GLEEVEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,958,335

Title: Treatment of gastrointestinal stromal tumors
Abstract:4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2- ylamino)phenyl]-benzamide of the formula I ##STR1## or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
Inventor(s): Buchdunger; Elisabeth (Neuenburg, DE), Capdeville; Renaud (Riedesheim, FR), Demetri; George Daniel (Brookline, MA), Dimitrijevic; Sasa (Habsheim, FR), Druker; Brian Jay (Portland, OR), Fletcher; Jonathan A. (Brookline, MA), Heinrich; Michael C. (Lake Oswego, OR), Joensuu; Heikki (Helsinki, FI), Silberman; Sandra Leta (Randolph, NJ), Tuveson; David (Berwyn, PA)
Assignee: Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) Oregon Health & Science University (Portland, OR)
Application Number:10/415,015
Patent Claim Types:
see list of patent claims
Use; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
imatinib mesylate
CAPSULE;ORAL021335-001May 10, 2001DISCNYesNo► Subscribe► SubscribeY
imatinib mesylate
CAPSULE;ORAL021335-002May 10, 2001DISCNYesNo► Subscribe► SubscribeY
imatinib mesylate
TABLET;ORAL021588-001Apr 18, 2003ABRXYesNo► Subscribe► SubscribeY
imatinib mesylate
TABLET;ORAL021588-002Apr 18, 2003ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,958,335

PCT Information
PCT FiledOctober 26, 2001PCT Application Number:PCT/EP01/12442
PCT Publication Date:May 02, 2002PCT Publication Number: WO02/34727

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus